Study: Clinical evidence review for Cannabidiol

This 2024 paper is a narrative review of cannabidiol, cannabis-derived products, regulation, pharmacology, and clinical use. It offers a useful overview of why purified CBD, commercial extracts, and broader cannabis products should not be treated as interchangeable. Its value is real, but it remains a narrative review, not a new trial, so its conclusions should be read as framing and synthesis rather than definitive proof.

Read More

Study: Cannabis Harm Reduction Strategies

This 2025 review maps cannabis harm reduction strategies across legal, social, and health-related domains, from packaging rules and driving policies to cannabis social clubs and product testing. It is useful as a typology and policy overview, but it does not establish which measures work best because the evidence base is mixed and often qualitative. For readers and clinicians, the value here is in clearer thinking about risk reduction, not in assuming these interventions are already proven.

Read More